Aqemia

Aqemia

Accelerates drug discovery using quantum AI

Overview

placeholder

About Aqemia

Simplify's Rating
Why Aqemia is rated
C+
Rated B on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Data & Analytics

AI & Machine Learning

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Grant

Total Funding

$124.9M

Headquarters

Paris, France

Founded

2019

People at Aqemia

People at Aqemia who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • $8.85B RNA small molecule market growing at 22.7% CAGR by 2032.
  • Big pharma validates RNA approaches with $2B Merck-Skyhawk collaboration in 2025.
  • Physics platform cuts discovery time from 5-6 years to under two years.

What critics are saying

  • Small-molecule RNA targeting fails 45-65% due to dynamic structures in 12-18 months.
  • France 2030 grant faces 50-70% failure risk screening flexible RNA in 9-15 months.
  • Sanofi partnership fails 40-60% if RNA delivery issues persist by 2027.

What makes Aqemia unique

  • Physics-based generative AI designs novel molecules without experimental data.
  • Combines quantum-inspired physics and statistical mechanics for scalable drug invention.
  • Targets RNA and proteins with validated in vivo efficacy in animal models.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$124.9M

Above

Industry Average

Funded Over

6 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison
Coming Soon

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

1%

Recently Posted Jobs

Sign up to get curated job recommendations

Aqemia is Hiring for 11 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →